Salute e Benessere
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
As a first step, the aim is to develop powder-based intranasal vaccine candidates, focusing on Abera's influenza vaccine candidate. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic.
The collaboration is funded by Abera through various previously received grants, mainly from (the Coalition for Epidemic Preparedness Innovation).
:
Nikolaj Sørensen, President and CEO
Lena Wange , IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million , and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
For more information on Orexo, visit www.orexo.com . Follow Orexo on X, LinkedIn, and YouTube.
Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.
Abera Bioscience AB is a Swedish vaccine and biotechnology company founded in 2012, originating from molecular biology research at Vrije Universiteit Amsterdam and Stockholm University . Abera develops innovative vaccines based on proprietary and patented platform technologies. The vaccine candidates can be administered as nasal sprays and are fast and cost-effective to develop and produce. Using its platform technologies, the company has developed several vaccine candidates and is currently focused on two main areas: pneumococcal vaccines and pandemic preparedness. The company's lead candidate, Ab-01.12, is a nasal vaccine against pneumococci, being prepared for Phase 1 clinical trials.
Abera's BERA vaccine platform is based on bacterial particles known as OMVs (Outer Membrane Vesicles), which are decorated with a large number of disease-specific antigens. Vaccines based on the BERA platform can be administered as nasal sprays and create protection in both mucosal membranes and systemically in the body, aiming to protect against both disease and transmission. The platform technology enables the rapid development of new vaccine candidates as antigens can be replaced in a plug-and-play manner.
The information was submitted for publication at 8.00 am CET on December 17 , 2024.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/orexo-enters-into-collaboration-with-abera-to-develop-nasal-powder-vaccines-based-on-the-amorphox-technology-302333487.html